When Time Meets Power CV Risk Protection Tools & Apps 5 years of EMPA-REG Outcome Let's Talk Prof Christoph Wanner’s take on EMPA-KIDNEY Prescribing Information Voice of CRM Previous Next What is the clinical relevance of broader patient population studied in EMPA-KIDNEY? 25/01/2024 | Author: Boehringer Ingelheim Document ID: PC-SG-102237 Voice of CRM PEKP||VoCRM Video - Managing Initial eGFR Dip VoCRM||What is the clinical relevance of broader patient population studied in EMPA-KIDNEY? VoCRM||How are CRM conditions linked? RELATED CONTENT Read more 02:44 VoCRM Video - Managing Initial eGFR Dip Watch now Opens in new tab Read more 03:04 VoCRM||How are CRM conditions linked? Watch now Opens in new tab Home Metabolic Empagliflozin Voice of CRM VoCRM||What is the clinical relevance of broader patient population studied in EMPA-KIDNEY?
